Transdermal Estradiol with Micronized Progesterone: Optimal Hormone Therapy for Perimenopause – RCT
This randomized controlled trial evaluated the efficacy and safety of various hormone replacement therapy (HRT) regimens in 840 perimenopausal women aged 45-55 years. Participants were allocated to receive either transdermal 17β-estradiol with micronized progesterone, oral conjugated estrogens with medroxyprogesterone acetate, transdermal estradiol with dydrogesterone, or non-hormonal therapy for 24 months. Vasomotor symptom reduction was the main result, with safety profiles, metabolic paramete
Authors
- Мария Анатольевна Денисова
- Aminat Magomedova (ORCID: https://orcid.org/0000-0003-2881-9643)
- Magomed Bashir Khavazhevich Izmailov
- Akhmed Magomedovich Abuev
- Aida Isaewna Mogushkova
- Lina Olegovna Betsukova
- Fatima Abdulgamidovna Dzhahbarova
- Ivan Sergeevich Trishkin
- Sekinat Albertovna Alimirzoeva
Publication Details
- Journal
- Journal Of Biochemical Technology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.51847/7eoq7of0w6
- Primary Topic
- Estrogen and related hormone effects
- Type
- article
- Field-Weighted Citation Impact
- 0.00